0001522860 false 0001522860 2022-07-25 2022-07-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares











Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 25, 2022




Acutus Medical, Inc.

(Exact name of Registrant as Specified in Its Charter)



Delaware 001-39430 45-1306615

(State or Other Jurisdiction

of Incorporation) 

(Commission File Number)

(IRS Employer

Identification No.) 


2210 Faraday Ave., Suite 100

Carlsbad, CA

(Address of Principal Executive Offices)   (Zip Code)


Registrant’s Telephone Number, Including Area Code: (442) 232-6080


Not Applicable

(Former Name or Former Address, if Changed Since Last Report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
Common Stock, par value $0.001 AFIB The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Effective July 25, 2022, and in accordance with the terms of the Acutus Medical, Inc. 2011 Equity Incentive Plan and the Acutus Medical, Inc. 2020 Equity Incentive Plan (the “Incentive Plans”), the Board of Directors (the “Board”) of Acutus Medical, Inc. (the “Company”) reduced the exercise price of outstanding options to purchase the Company’s common stock held by employees of the Company who were employed on July 25, 2022 (and who had not provided a notice of resignation prior to such date) (the “Designated Options”) to $1.34 per share, which was the closing price for the Company’s common stock on July 25, 2022. The exercise price reduction includes options held by, among others, the Company's Chief Executive Officer, David Roman, with respect to 127,335 shares (with original exercise prices ranging from $2.41 to $13.66).


Except for the reduction in the exercise price of the Designated Options, all outstanding stock options continue to remain outstanding in accordance with their current terms and conditions as set forth in the Incentive Plans and award agreements thereunder.


Item 9.01.Financial Statements and Exhibits.






104   Cover Page Interactive Data File (embedded within the Inline XBRL document)






Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


  Acutus Medical, Inc.
Date: July 29, 2022 By: /s/ Tom Sohn
    Tom Sohn
    SVP, General Counsel